Cilomilast

Known as: 4-cyano-4-(3-cyclopentoxy-4-methoxy-phenyl)-cyclohexane-1- carboxylic acid, Cilomilast [Chemical/Ingredient], Cis-4-Cyano-4-(3-(Cyclopentyloxy)-4-Methoxyphenyl)Cyclohexanecarboxylic Acid 
 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (2)

ArifloSB 207499

Broader (3)

Cyclohexanecarboxylic AcidsNitrilesPhosphodiesterase 4 Inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
Psoriasis and psoriatic arthritis are common clinical conditions that negatively impact health-related quality of life and are… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Review
2005
Review
2005
Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease
Inhibitors of phosphodiesterase type 4 (PDE4) act by increasing intracellular concentrations of cyclic AMP, which has a broad… (More)
Is this relevant?
2005
2005
Cilomilast, tacrolimus and rapamycin modulate dendritic cell function in the elicitation phase of allergic contact dermatitis.
BACKGROUND Cilomilast and tacrolimus as well as rapamycin are potential drugs for the treatment of allergic skin diseases like… (More)
Is this relevant?
2004
2004
Cytokines modulate cilomilast response in lung fibroblasts.
Fibroblasts, as a major source of extracellular interstitial connective tissue matrix, play an important role in wound healing… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.
Cilomilast (Ariflo), a new oral phosphodiesterase-4 selective inhibitor, improves lung function in chronic obstructive pulmonary… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 4
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD.
BACKGROUND Inflammation in chronic obstructive pulmonary disease (COPD) is characterised by increased neutrophilic infiltration… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2002
2002
Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-alpha and neutrophil elastase.
Tissue destruction, resulting in emphysema, can be a consequence of several pathologic processes. The current study evaluated the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 7
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study
BACKGROUND Chronic obstructive pulmonary disease (COPD) is a common, progressive respiratory disease that causes great morbidity… (More)
Is this relevant?
Review
2001
Review
2001
Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.
Cilomilast (Ariflo, SB-207499) is an orally-active, second generation phosphodiesterase (PDE) inhibitor that may be effective in… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
From a series of benzamide derivatives, roflumilast (3-cyclo-propylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?